PDX gene expression
Investigation of the anti-tumor activity of the potent, highly selective, orally bioavailable CHK1 inhibitor (CHK1i), SRA737, in both acquired PARPi-resistant BRCA1/2 mutant and CCNE1amp high-grade serous ovarian cancer (HGSOC) models. We analyzed gene expression in five patient derived xenografts (PDX) that responded to CHK1i and three PDX that had a poor response to CHK1i.
- Type: RNASeq
- Archiver: European Genome-Phenome Archive (EGA)
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
Dataset ID | Description | Technology | Samples |
---|---|---|---|
EGAD50000000116 | Illumina NovaSeq 6000 | 8 |
Publications | Citations |
---|---|
CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and <i>CCNE1</i> amplified ovarian cancer.
iScience 27: 2024 109978 |
1 |